Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | STAT3 | P40763 | 1/20 | 0.37 |
| ▸ | PGK1 | P00558 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.34 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.33 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.33 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1921609 | 0.95 | GABRA1 (0.40) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL1920948 | 0.78 | GABRA1 (0.48) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL4828805 | 0.71 | SLC6A2 (0.51) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL10494053 | 0.71 | STAT3 (0.45) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL23777733 | 0.71 | STAT3 (0.42) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL4203797 | 0.70 | MAPT (0.48) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL15557828 | 0.70 | STAT3 (0.47) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL30208125 | 0.70 | MAPT (0.48) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL7078684 | 0.70 | STAT3 (0.44) | GABRA1GABRG2GABRB3GABRA3GABRA2 | |
| SCHEMBL355085 | 0.70 | ALOX15 (0.47) | GABRA1GABRG2GABRB3GABRA3GABRA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283476-B2 | Transition metal catalyzed synthesis of 2H-indazoles | SANOFI (FR) | 2012-10-09 | — | — | US | disclosed |
| EP-2134682-B1 | A TRANSITION METAL CATALYZED SYNTHESIS OF N-AMINOINDOLES | SANOFI SA (FR) | 2011-12-14 | — | — | EP | disclosed |
| US-8026375-B2 | Transition metal catalyzed synthesis of N-aminoindoles | SANOFI-AVENTIS (FR) | 2011-09-27 | — | — | US | disclosed |
| EP-2170833-B1 | A TRANSITION METAL CATALYZED SYNTHESIS OF 2H-INDAZOLES | SANOFI AVENTIS (FR) | 2011-06-01 | — | — | EP | disclosed |
| US-20100234601-A1 | Transition metal catalyzed synthesis of 2H-indazoles | SANOFI-AVENTIS (FR) | 2010-09-16 | — | — | US | disclosed |
| US-20100168429-A1 | Transition metal catalyzed synthesis of N-aminoindoles | SANOFI-AVENTIS (FR) | 2010-07-01 | — | — | US | disclosed |
| EP-2170833-A1 | A TRANSITION METAL CATALYZED SYNTHESIS OF 2H-INDAZOLES | Sanofi-Aventis (FR) | 2010-04-07 | — | — | EP | disclosed |
| EP-2134682-A1 | A TRANSITION METAL CATALYZED SYNTHESIS OF N-AMINOINDOLES | Sanofi-Aventis (FR) | 2009-12-23 | — | — | EP | disclosed |
| WO-2009000411-A1 | A TRANSITION METAL CATALYZED SYNTHESIS OF 2H-INDAZOLES | SANOFI-AVENTIS (FR) | 2008-12-31 | — | — | WO | disclosed |
| WO-2008125207-A1 | A TRANSITION METAL CATALYZED SYNTHESIS OF N-AMINOINDOLES | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168429-A1 | Transition metal catalyzed synthesis of N-aminoindoles | NAT1, H1-3, H1-2 | GABRA1 3378/4885GABRG2 3763/4885GABRB3 4156/4885 |
| US-20100234601-A1 | Transition metal catalyzed synthesis of 2H-indazoles | H1-3, H1-2, H1-4 | GABRA1 2043/4885GABRG2 3163/4885GABRB3 2291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.